Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Recent Advances in Inflammation and Allergy Drug Discovery is Scopus-indexed (Q3, CiteScore 2), WoS ESCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 2772-2708Verify ISSN ↗2772-2716Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 188 / 278 | 32nd | Q3 |
| Immunology and Allergy | 182 / 234 | 22nd | Q4 |
| Drug Discovery | 128 / 161 | 20th | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2021–present, best quartile Q3, CiteScore 2.
Recent Advances in Inflammation and Allergy Drug Discovery is Q3 in Pharmacology (medical) (rank 188 of 278), Q4 in Immunology and Allergy (rank 182 of 234) and Q4 in Drug Discovery (rank 128 of 161), by CiteScore 2025.
Recent Advances in Inflammation and Allergy Drug Discovery is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2, which places it in quartile Q3 at the 32nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.391, quartile Q3, with an H-index of 40.
Recent Advances in Inflammation and Allergy Drug Discovery is published by Bentham Science Publishers. Its print ISSN is 2772-2708 and its online ISSN is 2772-2716.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Recent Advances in Inflammation and Allergy Drug Discovery has an h-index of 9 and a 2-year mean of 0.86 citations per paper (OpenAlex). Its Scopus CiteScore is 2, quartile Q3. On 2-year citations it ranks #196 of 271 Scopus journals in Pharmacology (medical).
Recent Advances in Inflammation and Allergy Drug Discovery published 26 papers in 2025; its busiest recent year was 2024 with 43. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 90 research articles (2024–2026), authors are most often from India (51.4%), Iran (16.1%) and Italy (10%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.